Zacks Investment Research downgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS) from a hold rating to a sell rating in a report published on Tuesday.
According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
SYRS has been the topic of a number of other research reports. Oppenheimer set a $26.00 price target on shares of Syros Pharmaceuticals and gave the company a buy rating in a research note on Thursday, November 1st. HC Wainwright reaffirmed a hold rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday, August 8th. BidaskClub downgraded shares of Syros Pharmaceuticals from a sell rating to a strong sell rating in a research note on Wednesday, October 17th. Cann reissued a buy rating and issued a $26.00 target price on shares of Syros Pharmaceuticals in a research note on Tuesday, August 7th. Finally, JMP Securities set a $33.00 price target on shares of Syros Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, November 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $19.00.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, November 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.02). The company had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.72 million. As a group, sell-side analysts anticipate that Syros Pharmaceuticals will post -1.87 EPS for the current year.
A number of institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its holdings in Syros Pharmaceuticals by 10.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 77,654 shares of the company’s stock worth $925,000 after acquiring an additional 7,062 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Syros Pharmaceuticals by 2.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 369,959 shares of the company’s stock worth $4,406,000 after acquiring an additional 8,286 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Syros Pharmaceuticals by 299.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock worth $168,000 after acquiring an additional 9,691 shares in the last quarter. Rhumbline Advisers grew its holdings in Syros Pharmaceuticals by 87.6% during the 2nd quarter. Rhumbline Advisers now owns 22,472 shares of the company’s stock worth $229,000 after acquiring an additional 10,494 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Syros Pharmaceuticals during the 2nd quarter worth about $119,000. Institutional investors own 60.74% of the company’s stock.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.